A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation
Journal of Medicinal Chemistry · 28.08.2025 · 68 (16) · 17598-17610
DOI: 10.1021/acs.jmedchem.5c01294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.08.2025. Verfasst von Yuchen Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Radiopharmaceuticals, Antigens, Surface. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In this study, we reported a bispecific radiotracer [99mTc]Tc-HFaPSMA to improve the diagnostic sensitivity of prostate cancer (PCa). [99mTc]Tc-HFaPSMA was prepared by 99mTc radiolabeling of a HYNIC-conjugated bispecific biomolecule HFaPSMA, which combines a PSMA-targeting motif (PhPSMA), a FAP-targeting ligand (GFAPI), a symmetric PEG4-N-bis(PEG4-acid) linker, and a chelator (HYNIC). Preclinical studies showed faster clearance and higher tumor uptake than that of its corresponding single-target radiotracers ([99mTc]Tc-HPSMA and [99mTc]Tc-HGFAPI). Clinical SPECT/CT matched the resolution of [18F]FDG and [18F]F-PSMA-1007 PET/CT for primary and metastatic lesions. [99mTc]Tc-HFaPSMA showed excellent targeting specificity for both PSMA and FAP. It has the potential to overcome diagnostic limitations due to PSMA heterogeneity and is expected to advance its application in radioligand therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277W Yanta Road, Xi'an 710061, China.
ORCID-Profile: Bing Jia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Li, X., Li, C., Xing, H., Gao, R., & Jia, B. (2025). A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation. Journal of Medicinal Chemistry, 68(16), 17598-17610. https://doi.org/10.1021/acs.jmedchem.5c01294
Vancouver
Wang Y, Li X, Li C, Xing H, Gao R, Jia B. A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation. Journal of Medicinal Chemistry. 2025;68(16):17598-17610. doi:10.1021/acs.jmedchem.5c01294
BibTeX
@article{Wang2025,
author = {Wang, Yuchen and Li, Xinru and Li, Chenzhen and Xing, Huiyuan and Gao, Rui and Jia, Bing},
title = {A Novel PSMA/FAP-Specific Radiotracer 99mTc-HFaPSMA for Diagnosis of PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {16},
pages = {17598--17610},
doi = {10.1021/acs.jmedchem.5c01294}
}
EUVIMED